Anixa recently launched a Phase I trial of its breast cancer vaccine in patients who have completed treatment for early-stage, triple-negative breast cancer within the past three years and are currently tumor-free but at high risk for recurrence. 

Her company AltruBio focuses on novel therapeutics for immunological diseases, concentrating on unmet medical needs. The company’s lead candidate, therapeutic antibody neihulizumab, has demonstrated clinical proof of efficacy in treating multiple autoimmune and immune-mediated diseases.  

TFF Pharmaceuticals is on the hunt for new partners, and a recently-announced agreement with Catalent could help them land just that.

Executive president of MindMed, Miri Halperin Wernli, PhD, added: “LSD and psilocybin have recently become promising candidates for the treatment of various psychiatric and neurologic disorders, and thus a deeper understanding of their differential subjective effects in humans is needed. 

Cerevance has developed its proprietary, Nuclear Enriched Transcript Sort sequencing (NETSseq) platform to analyze postmortem human brain tissues to produce rich cell type–specific data sets. 

Portage Biotech: Clinical-stage oncology company dedicated to sourcing and acquiring the most promising early-stage assets available to build a pipeline of first-in-class/best-in-class therapeutic candidates. Currently, has well-established partnerships with both Bristol Myers Squibb and Merck.

Teclison, a Princeton, NJ-based clinical-stage biotechnology company developing innovative cancer therapeutics to induce tumor necrosis and enhance anti-tumor immunity, closed a $5.9m funding round.